Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “NANDROLONE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 901 records · Page 50Linked to original sources
PubMedDate not supplied

[Cytochemical evaluation of anabolic protein effectiveness in the treatment of prenatal dystrophy].

Cytochemical data are available on peripheral blood neutrophils from 16 babies suffering from prenatal dystrophy and hypoxic or traumatic encephalopathy. These exhibited statistically significant enhancement of acid and alkaline phosphatases, inhibited activity of myeloperoxidase, low percentage of glycogen and lipids. In response to protein enpit therapy combined with retabolil the enzymic profile of the neutrophils improved, glycogen and lipids concentrations normalized. The cytochemical method is advocated for individual evaluation of the trophicity, while protein-anabolic therapy as a metabolic adjuvant.

Acid Phosphatase↗
PubMedDate not supplied

[Local use of retabolil in the treatment of corneal pathology in experimental animals and clinical practice].

Experiments with 30 rabbits revealed enhanced corneal epithelium regeneration under the effect of local (epibulbar and subconjunctival) retabolil therapy. Clinically 15 patients with epithelial-endothelial corneal dystrophy were treated with retabolil, the treatment being effective in all the cases when the initial visual acuity was at least 0.1 diopters.

Administration, Topical↗
PubMed1993

Epidemiology, biochemistry and some results with treatment of postmenopausal osteoporosis.

The present chapter deals with postmenopausal osteoporosis. This is an important disease because it affects millions of people throughout the world. The most serious of the osteoporotic fractures, the hip fractures, needs hospitalization, causes a high degree of mortality, and results often in dependent people. Osteoporosis is thus a significant socioeconomic burden. At the menopause bone turnover increases and bone loss accelerates. Postmenopausal bone loss and osteoporosis may be prevented by oestrogen replacement therapy, but convincing therapy for established osteoporosis does not yet exist. Anabolic steroid therapy can, however, increase the bone mineral content a few percentages a year in postmenopausal osteoporotic women.

Aged↗
PubMed1993

Anabolic steroids in postmenopausal osteoporosis.

The anabolic steroids were first developed in the 1950's to provide the anabolic advantages of androgens with less androgenic action. They are widely used in the treatment of osteoporosis, although their effectiveness has only recently been demonstrated with the advent of bone densitometry. It is now established that their administration leads to a significant increase in bone mass in osteoporotic men and women associated with an apparent conversion of fat into muscle tissue. The bone gain is of the order of 3% per annum but the maximal effect is obtained in the first few months. The bone gain is probably due to stimulation of bone formation and is associated with elevation of serum albumin and fat-free skinfold thickness. The most serious side-effect with parenteral use is lowering of voice pitch but there is some evidence that oral anabolic steroids may adversely affect liver function. The optimum dose and duration of therapy has not yet been established.

Adult↗
PubMedDate not supplied

[Osteoporosis in phlebology].

Patient often think that the pains of their extremities (especially during the night) are caused by a plebo or an angiopathy whereas they are in fact due to a vertebral or lumbar discal affection. 84 patients with osteoporosis were treated by an intramuscular injection of deca-durabolin (25 mg/month) and calcium phosphate (tertiare). Results were satisfactory: six months later, 62 patients no longer suffered, 13 had felt improvement and 2 remained unchanged.

Aged↗
PubMed1975

Glucocorticoids and mammalian motor nerve excitability.

Short-term treatment of cats with high doses of triamcinolone and related steroids strikingly increased the capacity of soleus motoneurons to generate posttetanic stimulus-bound repetition (SBR) and the obligatory postetanic potentiation (PTP) of muscle. The edrophonium chloride (Tensillon)-induced SBR and twitch potentiation were likewise augmented. These effects reflect an increase in the excitability of the motoneuron. This glucocorticoid effect suggests that the motoneuron is the site of the antimyasthenic action of the hormone. Certainly, the enhanced SBR is a neuronal representation of the adverse epileptogenic action of the glucocorticoids. The glucocorticoid effect on motoneuron outlasts the dosing period, suggesting an underlying alteration in the neuron. Other glucocorticoids caused the same effects, but varied in their potencies. Mineralocorticoids were less effective. The single androgen that was tested proved to be minimally effective.

Animals↗
PubMed1999

Development and evaluation of a competitive time-resolved immunofluorometric assay for the estrogen-regulated protein pS2.

We have developed a competitive assay to measure the estrogen-regulated protein pS2. A monoclonal pS2 antibody (mAb) and a biotinylated pS2 peptide are used, with time-resolved fluorometry as a detection technique. The assay has a detection limit of 16 ng/mL and is precise (within-run and day-to-day Cvs 3-12%). We used this assay to determine steroid hormone activity of six steroids in cell culture, both in terms of time course and dose response. pS2 concentrations in the tissue culture supernatant of the BT-474 breast carcinoma cell line were significantly higher when estradiol was the stimulating steroid. There was a significant time course and dose response observed for estradiol, but not for the other steroids. The availability of a sensitive, reliable, and convenient method for quantifying pS2 will allow for many research applications including the screening of natural and synthetic compounds for putative estrogenic activity.

Aldosterone↗
PubMed2000

Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen-induced LNCaP cells.

BACKGROUND: Human prostate-specific antigen (PSA) and human kallikrein 2 (hK2) are expressed primarily by prostate epithelial cells. PSA and hK2 both exist as free protein and complexed with protease inhibitors (e.g., alpha1-antichymotrypsin, ACT) in serum. The expression of PSA and hK2 in LNCaP cells is upregulated by androgen. METHODS: LNCaP, a prostate cancer cell line that secretes both PSA and hK2, was used as a model to study the biosynthesis and processing of PSA and hK2 upon androgen induction. RESULTS: Precursor (zymogen or pro) forms of both PSA and hK2 were detected in spent media of induced and noninduced LNCaP cells, indicating that PSA and hK2 are secreted as proPSA (pPSA) and prohK2 (phK2), respectively, and are converted to the mature forms extracellularly. A 3-fold higher ratio of mature to pPSA was detected in the spent media of mibolerone-induced LNCaP cells compared to noninduced cells. In addition to the inactive proform of PSA, more than half of the mature unclipped PSA present in the spent media did not complex with exogenously added ACT. Spent media of mibolerone-induced LNCaP cells contained nearly 100% mature hK2, whereas the spent media of noninduced cells contained mostly phK2. CONCLUSIONS: These results indicate that androgens not only upregulate the expression of these kallikreins, but also have a significant effect on the processing of PSA and hK2. These results also show that LNCaP cells express a heterogeneous mixture of inactive PSA and hK2 forms that may serve as a model for the genesis of these forms in physiological fluids. These findings may also provide insights into the forms and ratios of PSA and hK2 in normal and malignant breast tissues.

Antibodies, Monoclonal↗
PubMed2000

Measurement of 19-nortestosterone and its esters in equine plasma by high-performance liquid chromatography with tandem mass spectrometry.

A high-performance liquid chromatographic-tandem mass spectrometric (HPLC/MS/MS) method for the determination of 19-nortestosterone and its esters (cyclopentanepropionate, phenylpropionate, and decanoate) in equine plasma is achieved using an atmospheric pressure chemical ionization (APCI) interface in selected reaction monitoring (SRM) mode. The two internal standards used were 16,16, 17-(2)H(3)-19-nortestosterone for 19-nortestosterone and methenolone acetate for its esters. The steroids studied were extracted from plasma samples with a mixture of diethyl ether/n-hexane (9:1, v/v). The quantification limits for 19-nortestosterone, 19-nortestosterone cyclopentanepropionate, 19-nortestosterone phenylpropionate, and 19-nortestosterone decanoate were 0.16, 5.0, 0.1, and 2.0 ng/mL, respectively, when 2 mL of plasma were used. The recoveries of most of the steroids were 71.6-101.0% except for the decanoate, which could be recovered to about 39.8%. The responses were linear, with correlation coefficients varying from 0.9897 to 0.9999 in the concentration range of 0.1 to 50.0 ng/mL for the steroids studied. When applied to equine (mare) plasma samples, the present method allowed detection of 19-nortestosterone up to 23 days after an intra-muscular injection of 400 mg as the decanoate.

Anabolic Agents↗